Allergy Drops During Pregnancy: What to Know

Generally yes, if you are already established on sublingual immunotherapy at a stable dose, continuing during pregnancy is widely considered acceptable under your provider's guidance. The common clinical view is that the higher-risk period is the build-up phase, and a patient already at a steady maintenance dose has passed that stage, so the risk profile is reassuring. Many providers keep patients at their existing maintenance dose rather than increasing it during pregnancy. This is not a blanket rule, however, and the decision should be made with your obstetric and allergy providers, who will consider your overall health and how well your symptoms are controlled. Tell your care team promptly when you learn you are pregnant so they can confirm whether and how to continue, and so your plan reflects your specific circumstances rather than a general guideline.

Starting immunotherapy for the first time during pregnancy is generally not recommended. The main reason is that beginning treatment requires a build-up phase, the period when the risk of a reaction is comparatively higher, and clinicians prefer to avoid initiating that phase during pregnancy as a precaution. This is about timing and caution rather than evidence that the drops harm a pregnancy. In most cases, the practical advice is to wait until after pregnancy to begin immunotherapy, while managing allergy symptoms in the meantime with approaches your provider considers appropriate for pregnancy. If you feel your situation is unusual, raise it with your provider, since the decision is individualized. But as a general approach, new starts are typically deferred, whereas established treatment is often continued.

Pregnancy does not change the fundamental side-effect profile of sublingual allergy drops, which remains predominantly mild and local: mouth, throat, or ear itching and occasional mild stomach upset, with systemic reactions exceptionally rare. What changes is the decision-making framework around the treatment, particularly the caution about dose increases and new starts, rather than the nature of the reactions themselves. Because pregnancy is a period where any reaction is approached carefully, providers often keep patients at a stable maintenance dose and avoid build-up. If you experience the usual mild local reactions while pregnant and continuing under guidance, they are managed as they normally would be. Any systemic symptoms, such as breathing difficulty or widespread hives, are an emergency in pregnancy just as at any other time and require prescribed epinephrine if instructed and immediate care.

The standard reason is precaution around the build-up phase. When immunotherapy begins, the dose is gradually increased, and this build-up is the period associated with a comparatively higher chance of a reaction. Clinicians generally prefer not to introduce that phase during pregnancy, choosing instead to defer a new start until afterward. This conservative stance reflects an emphasis on minimizing avoidable risk during pregnancy rather than any established evidence that the drops cause harm to the pregnancy. By contrast, a patient already at a stable maintenance dose has moved past the build-up phase, which is why continuing established treatment is viewed differently from starting new. The decision in any individual case rests with your providers, who weigh your treatment stage, symptom burden, and overall health rather than applying the guidance rigidly.

Breastfeeding raises separate questions from pregnancy, and the appropriate approach should be confirmed with your provider rather than assumed. In general, the predominantly local nature of sublingual immunotherapy and its mechanism are reasons clinicians often view continuing established treatment as reasonable while breastfeeding, but this is an individualized decision. As with pregnancy, the considerations are about timing and caution rather than a known harm, and your provider will weigh your treatment stage and overall situation. If you are breastfeeding and on drops, or considering them, discuss it directly with your allergy provider and let your pediatric and obstetric clinicians know, so everyone is aligned. Because guidance can depend on your specific circumstances and current recommendations, relying on your care team's advice is the safest course.